Wedbush Maintains Underperform on Eikon Therapeutics, Lowers Price Target to $5

Eikon Therapeutics, Inc.

Eikon Therapeutics, Inc.

EIKN

0.00

Wedbush analyst Robert Driscoll maintains Eikon Therapeutics (NASDAQ: EIKN) with a Underperform and lowers the price target from $7 to $5.